Search clinical trials for: AMG 552

Total 1937 results

The Cleveland Clinic
Amgen

Completed

A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients

Hyperparathyroidism

United States
Amgen
Immunex Corporation

Completed

The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

Psoriasis
National Cancer Institute (NCI)

Withdrawn

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma
Amgen

Completed

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Locally Recurrent and Metastatic Breast Cancer
Boston Medical Center
Amgen

Withdrawn

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Carcinoid Syndrome

United States
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States, Australia, New Zealand
Amgen
National Cancer Institute (NCI)

Completed

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

Sarcoma | Lymphoma | Small Intestine Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Tulane University Health Sciences Center

Completed

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
University of Pittsburgh
Amgen

Withdrawn

Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants

Rheumatoid Arthritis

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Radiation Toxicity | Oral Complications | Drug/Agent Toxicity by Tissue/Organ

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Lymphoma | Leukemia | Oral Complications

United States
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
Pierre Fabre Dermatology

Completed

Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects

Healthy Volunteers

Germany
Arbeitsgemeinschaft medikamentoese Tumortherapie
Amgen

Terminated

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

KRAS Wild Type | Resectable Type II Gastric Adenocarcinoma

Austria
Seattle Children's Hospital
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis | Juvenile Rheumatoid Arthritis | Juvenile Chronic Polyarthritis

United States
Amgen

Completed

Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

Rheumatoid Arthritis
Amgen
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis

Psoriasis
Amgen

Completed

Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease

Chronic Kidney Disease | Kidney Disease
Amgen

Completed

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Cancer | Anemia
Amgen

Completed

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

End Stage Renal Disease | Secondary Hyperparathyroidism
Bayer
Amgen

Completed

Sorafenib/Docetaxel Dose Escalation Trial

Neoplasms

United States
Amgen

Completed

AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies

Cancer
Amgen

Completed

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Tumors
Amgen

Completed

Enbrel® in Psoriatic Arthritis

Psoriasis
Amgen

Completed

Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.

Anemia
Amgen
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis

Psoriasis
Amgen
Immunex Corporation

Completed

Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis
Amgen
Immunex Corporation

Completed

Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012

Rheumatoid Arthritis
Amgen

Completed

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

Carcinoma | Colorectal Cancer
Amgen
Immunex Corporation

Completed

16.0040 Ankylosing Spondylitis Study

Ankylosing Spondylitis
Amgen

Completed

Chemotherapy Related Anemia

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

Normal PBPC Donors
Amgen

Completed

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Advanced Renal Cell Carcinoma
Amgen

Completed

Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

Secondary Hyperparathyroidism | Chronic Renal Insufficiency
Amgen

Completed

Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels

End Stage Renal Disease
Amgen

Completed

A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood

Breast Cancer | Ovarian Cancer | Lung Cancer
Amgen

Completed

Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)

End Stage Renal Disease
Amgen

Completed

Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

Neutropenia
Amgen

Completed

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis

End Stage Renal Disease | Secondary Hyperparathyroidism
Amgen

Completed

A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)

Hyperparathyroidism, Primary
Amgen

Completed

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Cancer | Anemia | Non-Myeloid Malignancies
Amgen

Completed

NESP Pediatric Study

End Stage Renal Disease | Pre-dialysis
Amgen

Completed

Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Chronic Kidney Disease | Kidney Disease
Amgen

Completed

Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer

Cancer | Anemia
Amgen

Completed

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

End Stage Renal Disease | Secondary Hyperparathyroidism
Amgen

Completed

Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy

Anemia | Solid Tumors
Amgen

Completed

Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy

Stomatitis
Amgen

Completed

12-month Study of AMG 073 in Renal Osteodystrophy

Renal Osteodystrophy
Amgen

Completed

A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism

Hyperparathyroidism, Primary
Amgen

Completed

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Hyperparathyroidism | Parathyroid Neoplasms

3

Subscribe